Mirmohammadsadeghi Amirhossein, Gharipour Mojgan, Roohafza Hamidreza, Dianatkhah Minoo, Sadeghi Masoumeh
Cardiac Rehabilitation Research Center, medical student, Hormozgan University of Medical Sciences, Hormozgan, Iran.
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran.
Arch Med Sci Atheroscler Dis. 2018 Aug 24;3:e112-e118. doi: 10.5114/amsad.2018.77820. eCollection 2018.
We previously highlighted the potential link between supplementation with selenium, as an antioxidant trace element, and changes in the levels of paraoxonase (POX1) and myeloperoxidase (MPO), as an antioxidant enzyme, in patients with documented cardiovascular disease (CVD). The aim of this study was to determine the effects of selenium supplementation on POX1 and MPO activity in patients with cardiovascular diseases (CVDs).
A total of 160 eligible patients were enrolled in the study. After performing some laboratory tests, including the measurement of blood selenium, triglyceride, cholesterol, and low- and high-density lipoprotein levels, the patients received 200 mg tablets of either selenium yeast or placebo. The medicines were taken orally, once daily after a meal for 60 days. Four weeks after the initial visit, the patients were invited for a follow-up visit, and interviews and non-laboratory evaluations, similar to those performed at baseline, were repeated. Compliance of patients for using selenium and placebo was measured by telephone. Medication compliance rates were monitored by telephone. The final assessments were conducted eight weeks after the beginning of the study.
There was no significant difference in cholesterol levels between intervention and control groups ( = 0.87). No significant changes in selenium levels were observed in either the selenium or the placebo group after the intervention ( = 0.44 and = 0.48, respectively). The two groups had a significant difference in terms of POX1 level ( = 0.039). No such difference was present in the case of MPO levels. Moreover, comparison of the values before and after the intervention showed no significant differences in the mean levels of any of the measured parameters.
According to the obtained results, the increased POX1 levels after selenium supplementation could be attributed to the positive effect of selenium on inhibiting lipid peroxidation as part of the complicated pathophysiology of CVD.
我们之前曾强调，作为一种抗氧化微量元素，补充硒与已确诊的心血管疾病（CVD）患者体内对氧磷酶（POX1）和髓过氧化物酶（MPO，一种抗氧化酶）水平的变化之间可能存在联系。本研究的目的是确定补充硒对心血管疾病（CVD）患者POX1和MPO活性的影响。
共有160名符合条件的患者纳入本研究。在进行了一些实验室检测，包括测量血硒、甘油三酯、胆固醇以及低密度和高密度脂蛋白水平后，患者服用200毫克的硒酵母片或安慰剂。这些药物口服，每日一次，饭后服用，持续60天。首次就诊四周后，邀请患者进行随访，并重复进行与基线时相同的访谈和非实验室评估。通过电话测量患者对硒和安慰剂的使用依从性。通过电话监测药物依从率。在研究开始八周后进行最终评估。
干预组和对照组的胆固醇水平无显著差异（P = 0.87）。干预后，硒组和安慰剂组的硒水平均未观察到显著变化（分别为P = 0.44和P = 0.48）。两组在POX1水平方面存在显著差异（P = 0.039）。MPO水平方面则无此差异。此外，干预前后各测量参数的平均水平比较均未显示出显著差异。
根据所得结果，补充硒后POX1水平升高可能归因于硒在抑制脂质过氧化方面的积极作用，这是CVD复杂病理生理学的一部分。
